SNY Sanofi

By Adria Calatayud

Sanofi aims to generate annual sales of more than 10 billion euros ($10.76 billion) by 2030 from recently launched and future pharmaceutical products to complement growth in its blockbuster anti-inflammatory drug Dupixent and vaccines.

The French pharmaceutical company said Thursday that it will focus research-and-development efforts going forward on strengthening its position in immunology treatments, and that it expects 25 data readouts for assets that are at mid to late stage of development and up to 19 regulatory submissions for its pharma assets in the next two years.

Sanofi's sales goal is supported by late-stage pipeline assets that have potential in multiple indications as well as recently launched drugs, including hemophilia treatment Altuviiio, blood-cancer drug Sarclisa and diabetes drug Tzield, it said.

The company said three of its pipeline assets--amlitelimab, frexalimab and SAR441566--have potential to exceed EUR5 billion in annual peak sales each, and that it sees potential for peak sales ranging from EUR2 billion to EUR5 billion for a further nine innovative medicines and vaccines.

"We are confident in our current product portfolio and the strength of our pipeline to deliver sustainable growth through 2030 and beyond," Sanofi Chief Executive Paul Hudson said.

In addition, the company reiterated its goal of generating more than EUR10 billion of annual sales from vaccines by 2030, including the recently launched Beyfortus for the prevention of respiratory syncytial virus, or RSV.

Dupixent sales are expected to grow at an annual rate of double percentage digits from 2023 to 2030, boosted by expected new indications such as chronic obstructive pulmonary disease as well as rising take-up for the diseases for which it is already approved, Sanofi said. The company has previously said it expects Dupixent sales to hit the EUR10 billion mark in 2023.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

December 07, 2023 02:05 ET (07:05 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.